FXYD2 antibody
Principal name
FXYD2 antibody
Alternative names for FXYD2 antibody
Sodium pump gamma chain, Na(+)/K(+) ATPase subunit gamma, ATP1C, ATP1G1, Sodium/potassium-transporting ATPase gamma chain,FXYD domain-containing ion transport regulator 2
SwissProt ID
O13001 (Xenla), P54710 (Human), Q04645 (Bovin), Q04646 (Mouse), Q04679 (Rat), Q04680 (Sheep)
Ncbi ID
9606, NP_001671.2, NM_021603, NM_001680, NP_067614, NP_001671, NP_031529.2, NM_007503, NM_017349, NM_145717, NM_001127489
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Paraffin Sections (P)
Background of FXYD2 antibody
- Kit Component:
- - KN306192G1, Fxyd2 gRNA vector 1 in pCas-Guide vector
- KN306192G2, Fxyd2 gRNA vector 2 in pCas-Guide vector
- KN306192D, donor vector containing left and right homologous arms and Luciferase-Puro functional cassette
- GE100003, scramble sequence in pCas-Guide vector - CRISPR Manual:
- CRISPR/CAS9 Genome Editing Manual
Immunoperoxidase of monoclonal antibody to FXYD2 on formalin-fixed paraffin-embedded human salivary gland. [antibody concentration 3 ug/ml]
FXYD2 monoclonal antibody (M01), clone 1C3-B3 Western Blot analysis of FXYD2 expression in Jurkat ( Cat # L017V1 ).
Western blot analysis of FXYD2 expression in HepG2 (A); mouse lung (B); rat brain (C) whole cell lysates.
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP302739 | FXYD2 (transcript variant b) |
||||
| Recombinant protein of human FXYD domain containing ion transport regulator 2 (FXYD2), transcript variant b | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
| TP305076 | FXYD2 (transcript variant a) |
||||
| Recombinant protein of human FXYD domain containing ion transport regulator 2 (FXYD2), transcript variant a | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY411967 | FXYD2 overexpression lysate |
|
 |
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. | ||
| LY419804 | FXYD2 overexpression lysate |
|
|
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR200074L2V | Lenti ORF particles, Fxyd2 (GFP-tagged) - Mouse FXYD domain-containing ion transport regulator 2 (Fxyd2), transcript variant a, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| MR200074L1V | Lenti ORF particles, Fxyd2 (Myc-DDK-tagged) - Mouse FXYD domain-containing ion transport regulator 2 (Fxyd2), transcript variant a, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR200370L2V | Lenti ORF particles, Fxyd2 (GFP-tagged ORF) - Rat FXYD domain-containing ion transport regulator 2 (Fxyd2), transcript variant a, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| RR200369L2V | Lenti ORF particles, Fxyd2 (GFP-tagged ORF) - Rat FXYD domain-containing ion transport regulator 2 (Fxyd2), transcript variant b, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| RR200370L1V | Lenti ORF particles, Fxyd2 (Myc-DDK-tagged ORF) - Rat FXYD domain-containing ion transport regulator 2 (Fxyd2), transcript variant a, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||
| RR200369L1V | Lenti ORF particles, Fxyd2 (Myc-DDK-tagged ORF) - Rat FXYD domain-containing ion transport regulator 2 (Fxyd2), transcript variant b, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||